GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Microbot Medical Inc (NAS:MBOT) » Definitions » Cash Flow from Operations

Microbot Medical (Microbot Medical) Cash Flow from Operations : $-7.75 Mil (TTM As of Mar. 2024)


View and export this data going back to 1992. Start your Free Trial

What is Microbot Medical Cash Flow from Operations?

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

For the three months ended in Mar. 2024, Microbot Medical's Net Income From Continuing Operations was $-2.37 Mil. Its Depreciation, Depletion and Amortization was $0.03 Mil. Its Change In Working Capital was $-0.53 Mil. Its cash flow from deferred tax was $0.00 Mil. Its Cash from Discontinued Operating Activities was $0.00 Mil. Its Asset Impairment Charge was $0.00 Mil. Its Stock Based Compensation was $0.45 Mil. And its Cash Flow from Others was $0.00 Mil. In all, Microbot Medical's Cash Flow from Operations for the three months ended in Mar. 2024 was $-2.42 Mil.


Microbot Medical Cash Flow from Operations Historical Data

The historical data trend for Microbot Medical's Cash Flow from Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Microbot Medical Cash Flow from Operations Chart

Microbot Medical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Operations
Get a 7-Day Free Trial Premium Member Only Premium Member Only -6.45 -7.25 -9.35 -11.55 -8.53

Microbot Medical Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Flow from Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.20 -1.85 -1.66 -1.82 -2.42

Microbot Medical Cash Flow from Operations Calculation

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

Microbot Medical's Cash Flow from Operations for the fiscal year that ended in Dec. 2023 is calculated as:

Microbot Medical's Cash Flow from Operations for the quarter that ended in Mar. 2024 is:


Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-7.75 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Microbot Medical  (NAS:MBOT) Cash Flow from Operations Explanation

For companies reported in indirect method, cash flow from operations contains six items:

1. Net Income From Continuing Operations:
Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Microbot Medical's net income from continuing operations for the three months ended in Mar. 2024 was $-2.37 Mil.

2. Depreciation, Depletion and Amortization:
Depreciation is a present expense that accounts for the past cost of an asset that is now providing benefits.
Depletion and amortization are synonyms for depreciation.
Generally:
The term depreciation is used when discussing man made tangible assets
The term depletion is used when discussing natural tangible assets
The term amortization is used when discussing intangible assets

Microbot Medical's depreciation, depletion and amortization for the three months ended in Mar. 2024 was $0.03 Mil.

3. Change In Working Capital:
Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities. Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow.

Microbot Medical's change in working capital for the three months ended in Mar. 2024 was $-0.53 Mil. It means Microbot Medical's working capital declined by $0.53 Mil from Dec. 2023 to Mar. 2024 .

4. Deferred Tax:
It is the cash flow generated from deferred tax.

Microbot Medical's cash flow from deferred tax for the three months ended in Mar. 2024 was $0.00 Mil.

5. Cash from Discontinued Operating Activities:
Net cash from all of the entity's discontinued operating activities.

Microbot Medical's cash from discontinued operating Activities for the three months ended in Mar. 2024 was $0.00 Mil.

6. Asset Impairment Charge:
It is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Microbot Medical's asset impairment charge for the three months ended in Mar. 2024 was $0.00 Mil.

7. Stock Based Compensation:
It is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Microbot Medical's stock based compensation for the three months ended in Mar. 2024 was $0.45 Mil.

8. Cash Flow from Others:
These are cash differences caused by the change of inventory, accounts payable, accounts receivable etc. For instance, if a company pays its suppliers slower, its cash position will build up faster. If a company receives payments from its customers slower, its account receivables will rise, and its cash position will grow more slowly (or even shrink).

Microbot Medical's cash flow from others for the three months ended in Mar. 2024 was $0.00 Mil.


Microbot Medical Cash Flow from Operations Related Terms

Thank you for viewing the detailed overview of Microbot Medical's Cash Flow from Operations provided by GuruFocus.com. Please click on the following links to see related term pages.


Microbot Medical (Microbot Medical) Business Description

Traded in Other Exchanges
Address
25 Recreation Park Drive, Unit 108, Hingham, MA, USA, 02043
Microbot Medical Inc is a pre-clinical medical device company. It specializes in developing next-generation micro-robotic medical technologies that can change the future of medicine. Their vision is to improve the quality of life of millions of patients globally by advancing micro-robotic technologies to perform surgical procedures and offer physicians and their patients less invasive and more precise solutions. The company's innovative platforms LIBERTY and Self-Cleaning Shunt (SCS) are in one of the fastest-growing segments in healthcare. The group continuously develops its technology with the goal to improve surgical outcomes worldwide. The firm presently holds domestic and global patents that strengthen its product portfolio and create barriers of entry.
Executives
Rachel Vaknin officer: Chief Financial Officer DROR 3/10, ZICHRON YAAKOV L3 3090216
Simon Sharon officer: General Manager & CTO 8 HAMADA STREET, ZICHRON YAACOV L3 3090708
Yoseph Bornstein director, 10 percent owner 16 IRUS STREET, ROSH HA'AYIN L3 4858022
Tal Baruch Wenderow director 1149, BEACON STREET, NEWTON MA 02461
Eyal Morag officer: Chief Medical Officer BONEY HAEAR 3 STREET, APT #13, TEL AVIV L3 6937303
Aileen Ptucha Stockburger director 26 WELLINGTON CT, BELLE MEADE NJ 08502
Harel Gadot director, 10 percent owner, officer: Chairman and CEO 5 VILLAGE LANE, HINGHAM MA 02043
Joseph Mona 10 percent owner 808 HAMPTON ST, COLUMBIA SC 29201
Prattipati Laxminarain director 3 HEWINS FARM ROAD, WELLESLEY MA 02481
Yoav Zvi Waizer director 8 HAVERED STREET, RAANANA L3 4352308
Moshe Shoham director 22 BEDOLACH STREET, HOSHAYA L3 1791500
Leon Lewkowicz 10 percent owner GORDON STREET 10, APARTMENT 7, TEL-AVIV L3 63458
Martin J. Madden director C/O MICROBOT MEDICAL INC., 175 DERBY STREET 27/1, HINGHAM MA 02043
Yehezkel Himelfarb officer: General Manager & COO 32 BEN YOSEF STREET, TEL-AVIV L3 6912530
Sandra Berkson 10 percent owner C/O SABER HOLDING GMBH, WEIN KRUMMBAUMGASSE C4 1020

Microbot Medical (Microbot Medical) Headlines

From GuruFocus